The Technical Analyst
Replimune Group Inc [REPL]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Replimune Group Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
4.39% $6.42
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 394.11 mill |
| EPS: | -3.16 |
| P/E: | -2.03 |
| Earnings Date: | May 16, 2024 |
| SharesOutstanding: | 61.39 mill |
| Avg Daily Volume: | 1.256 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.03 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.35x |
| Company: PE -2.03 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.474 (-77.03%) $-4.95 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 5.93 - 6.89 ( +/- 7.43%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Peeples-dyer Veleka | Buy | 32 000 | Stock Option (right to buy) |
| 2024-04-01 | Patel Sushil | Buy | 250 000 | Employee Stock Option (right to buy) |
| 2024-04-01 | Patel Sushil | Buy | 83 335 | Common Stock |
| 2024-04-01 | Pucci Paolo | Buy | 32 000 | Stock Option (right to buy) |
| 2024-04-01 | Xynos Konstantinos | Buy | 26 665 | Common Stock |
| INSIDER POWER |
|---|
| 74.46 |
| Last 98 transactions |
| Buy: 2 588 053 | Sell: 457 936 |
Forecast:
16:00 - $6.42
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $6.42
Forecast 2: 16:00 - $6.42
Forecast 3: 16:00 - $6.42
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $6.42 (4.39% ) |
| Volume | 0.577 mill |
| Avg. Vol. | 1.256 mill |
| % of Avg. Vol | 45.91 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For REPL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $7.81 | N/A | Active |
|---|
REPL
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-04-07 17:00:00 - Press Release
Interim Results From The Artacus Clinical Trial Of Rp1 Monotherapy In Solid Organ And Hematopoietic Cell Transplant Recipients With Skin Cancers Presented During Oral Presentation At The American Association Of Cancer Research (aacr) 2024 Annual Meeting
Rp1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patients rp1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patients
2024-04-04 08:00:00 - Press Release
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Woburn, mass., april 04, 2024 (globe newswire) -- replimune group, inc. (nasdaq: repl), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the grant of inducement equity awards to carolyn trott, the company's newly appointed senior vice president, quality assurance.
2024-03-26 07:30:00 - Press Release
Replimune Announces Appointment Of Sushil Patel To Ceo And Executive Leadership Transitions
Philip astley-sparke to transition from current role of ceo to executive chairman planned leadership changes position the company for commercialization preparations on track to submit rp1 biologics license application (bla) in 2h 2024 woburn, mass., march 26, 2024 (globe newswire) -- replimune group, inc. (nasdaq: repl), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the company's preparations for the commercial launch of rp1, pending regulatory submission and approval in anti-pd1 failed melanoma.
2024-02-08 08:00:00 - Press Release
Replimune Reports Fiscal Third Quarter 2024 Financial Results And Provides Corporate Update
Woburn, mass., feb. 08, 2024 (globe newswire) -- replimune group, inc. (nasdaq: repl), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended december 31, 2023, and provided a business update.
2023-12-28 08:00:00 - Press Release
Replimune To Present At The 42nd Annual J.p. Morgan Healthcare Conference
Woburn, mass., dec. 28, 2023 (globe newswire) -- replimune group, inc. (nasdaq: repl), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that philip astley-sparke, chief executive officer of replimune, will present at the 42nd annual j.p. morgan healthcare conference on monday, january 8, 2024 at 11:15 am pt at the westin st. francis hotel in san francisco, ca.
Latest News
2024-03-11 10:56:04 - Zacks Investment Research
How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
The average of price targets set by Wall Street analysts indicates a potential upside of 50.2% in Replimune Group, Inc. (REPL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-03-08 13:01:14 - Zacks Investment Research
What Makes Replimune Group, Inc. (REPL) a New Buy Stock
Replimune Group, Inc. (REPL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2024-02-23 10:56:08 - Zacks Investment Research
Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?
The consensus price target hints at a 70.6% upside potential for Replimune Group, Inc. (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2023-12-28 08:00:00 - GlobeNewsWire
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 AM PT at the Westin St. Francis Hotel in San Francisco, CA.
2023-12-05 11:39:22 - InvestorPlace
Why Is Replimune (REPL) Stock Down 48% Today?
Replimune (NASDAQ: REPL ) stock is falling hard on Tuesday after the clinical-stage biotechnology company shared a primary analysis of its CERPASS trial. This trial is evaluating RP1 alongside cemiplimab in the treatment of locally advanced or metastatic cutaneous squamous cell carcinoma.
2023-12-05 08:28:00 - Market Watch
Replimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals
Replimune Group Inc. shares REPL, +5.21% dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer therapy had failed to meet its primary goals in a clinical trial in skin cancer. The therapy, RP1, was studied in combination with cemiplimab, a Regeneron Pharmaceuticals Inc. REGN, +1.04% monoclonal antibody branded as Libtayo.
2023-08-14 17:28:47 - Seeking Alpha
Replimune: Q4 2023 Data Readouts Of RP1 Makes This A Must Watch
Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous squamous cell carcinoma, are expected Q4 of 2023. The cutaneous squamous cell carcinoma treatment market is expected to reach $16.86 billion by 2027. Potential to tap into neoadjuvant cutaneous squamous cell carcinoma setting with RP1 by combining it with Incyte's oral PD-L1 inhibitor INCB99280.
2023-07-09 01:22:08 - Seeking Alpha
Replimune: The Rise Of Oncolytic Virus Therapies In Cancer Treatment
The company's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Top-line results from the CERPASS clinical trial for RP1 combined with Libtayo for cutaneous squamous cell carcinoma are expected in Q3 2023. The partnership with Roche for RP2 and RP3 studies in challenging patient cohorts further emphasizes Replimune's resilience in positioning its treatments as leaders in the biotechnology sector.
2023-06-01 16:01:00 - GlobeNewsWire
Replimune to Present at the Jefferies Global Healthcare Conference
WOBURN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023 at 1:00 PM ET at the Marriot Marquis in New York NY.
2023-05-25 17:00:00 - GlobeNewsWire
Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 2-6, 2023.